Compare BVS & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | EMBC |
|---|---|---|
| Founded | 2011 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 617.1M | 524.1M |
| IPO Year | 2016 | 2021 |
| Metric | BVS | EMBC |
|---|---|---|
| Price | $10.50 | $9.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $14.00 | ★ $18.50 |
| AVG Volume (30 Days) | 440.5K | ★ 766.9K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 6.24% |
| EPS Growth | ★ 163.46 | 20.90 |
| EPS | 0.33 | ★ 0.74 |
| Revenue | ★ $568,087,000.00 | N/A |
| Revenue This Year | $7.52 | $1.17 |
| Revenue Next Year | $7.06 | N/A |
| P/E Ratio | $32.03 | ★ $12.97 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.81 | $8.47 |
| 52 Week High | $10.58 | $15.55 |
| Indicator | BVS | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 72.96 | 58.54 |
| Support Level | $8.43 | $8.60 |
| Resistance Level | N/A | $10.88 |
| Average True Range (ATR) | 0.36 | 0.35 |
| MACD | 0.14 | 0.14 |
| Stochastic Oscillator | 91.98 | 85.66 |
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.